Results 31 to 40 of about 15,116 (246)
Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease
Frontiers in Neurology, 2021 Background: The impact of Levodopa on the gut microbiota of Parkinson's disease (PD) patients has not been sufficiently addressed.Methods: We conducted a longitudinal study to examine the impact of Levodopa initiation on the gut microbiota composition of
Natalia Palacios +9 more
doaj +1 more source
Identification of TH Variants in Chinese Dopa-Responsive Dystonia Patients and Long-Term Outcomes
Frontiers in Neurology, 2021 Background: Dopa-responsive dystonia (DRD) is a movement disorder that is highly clinically and genetically heterogeneous. Our study summarizes clinical characteristics and long-term outcomes in patients with dopa-responsive dystonia with the aim of ...
Xin-yao Li +7 more
doaj +1 more source
Comparative adsorption of levodopa from aqueous solution on different activated carbons [PDF]
, 2009 Adsorption on activated carbon has been successfully used in wastewater and drinking water treatment plants for the removal of various pollutants. Among them, pharmaceutical compounds have become a growing issue. The present study has focused on levodopa
Quesada-Peñate, Isariebel +4 more
core +1 more source
Levodopa in the Treatment of Parkinson's Disease: Current Status and New Developments
Journal of Parkinson’s Disease, 2013 Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease (PD). Oral levodopa has been widely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor (DDCI ...
David Salat, Eduardo Tolosa
doaj +1 more source
ADMET and DMPK, 2022 Levodopa is routinely co-administered with carbidopa in the management of Parkinson’s disease. Although the aforementioned combination therapy is effective, there may be fluctuating plasma levels of levodopa after oral administration.
Emelia Priscilla Imbeah +8 more
doaj +1 more source
, 2005 Levodopa remains the mainstay treatment for Parkinson's disease (PD). Chronic treatment is associated with motor complications (MC) that marred the clinical benefit of levodopa.
Castro, A +17 more
core +5 more sources
Levodopa-equivalent doses during follow-up.
, 2018 Levodopa-equivalent doses during follow-up.
Young H. Sohn (116741) +8 more
core +1 more source
Levodopa-responsive Holmes head titubation caused by midbrain cavernoma hemorrhage
, 2021 Levodopa-responsive Holmes head titubation caused by midbrain cavernoma ...
SM Slootjes (14479878) +4 more
core
A regression analytical model of serum levodopa metabolic profile in Parkinson's disease
HeliyonAlthough levodopa and its metabolites in blood have been investigated in parkinsonian disorders for biomarkers, medication effects of levodopa-associated drugs remain unclear. In this study, we investigated levodopa associated metabolites to characterize
Akiko Chukyo +24 more
doaj +1 more source
Levodopa-equivalent dose and follow-up duration between the two groups.
, 2016 HNM-PD (closed circle) received higher levodopa-equivalent dose than LNM-PD (open circle) at similar follow-up duration. However, group (HNM-PD, solid line/LNM-PD, dotted line) and follow-up duration interaction was non-significant for levodopa ...
Jee Hyun Ham (2966889) +5 more
core +1 more source